Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$3.24 USD
+0.09 (2.86%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.23 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ZNTL 3.24 +0.09(2.86%)
Will ZNTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZNTL
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
Other News for ZNTL
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Commit To Buy Zentalis Pharmaceuticals At $2.50, Earn 22% Annualized Using Options
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. ? ZNTL
Qualcomm downgraded, Eli Lilly upgraded: Wall Street's top analyst calls